GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.
You may also be interested in...
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
GSK preparing to seize “a major opportunity to create a new leader in consumer h
Under Brian McNamara’s leadership, GSK Consumer Healthcare has begun to assemble a management team that combines talent from both GSK and Pfizer.